Gene · 3355
HTR1F: 5-hydroxytryptamine receptor 1F
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. HTR1F: 5-hydroxytryptamine receptor 1F. Genes, record 3355. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3355
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P30939 | 5-hydroxytryptamine receptor 1F | 366 | 3 | Ensembl, GeneID, HGNC |
Source UniProt
Patents34
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 35756 | P30939 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 5073 | P30939 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2004 | P30939 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2004 | P30939 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 5073 | P30939 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 393 | P30939 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 393 | P30939 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 299 | P30939 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 103364 | P30939 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 5239 | P30939 | Espacenet |
1 to 10 of 34
See all 34 patentsDrugs11
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ALMOTRIPTAN | CHEMBL1505 | Serotonin 1f (5-HT1f) receptor agonist | AGONIST | ChEMBL |
| ALMOTRIPTAN MALATE | CHEMBL1200521 | Serotonin 1f (5-HT1f) receptor agonist | AGONIST | ChEMBL |
| AMISULPRIDE | CHEMBL243712 | Serotonin (5-HT) receptor antagonist | ANTAGONIST | ChEMBL |
| DEXFENFLURAMINE | CHEMBL248702 | Serotonin (5-HT) receptor agonist | AGONIST | ChEMBL |
| DEXFENFLURAMINE HYDROCHLORIDE | CHEMBL1887891 | Serotonin (5-HT) receptor agonist | AGONIST | ChEMBL |
| ELETRIPTAN | CHEMBL1510 | Serotonin 1f (5-HT1f) receptor agonist | AGONIST | ChEMBL |
| ELETRIPTAN HYDROBROMIDE | CHEMBL1201003 | Serotonin 1f (5-HT1f) receptor agonist | AGONIST | ChEMBL |
| LASMIDITAN | CHEMBL3039520 | Serotonin 1f (5-HT1f) receptor agonist | AGONIST | ChEMBL |
| LASMIDITAN SUCCINATE | CHEMBL3039526 | Serotonin 1f (5-HT1f) receptor agonist | AGONIST | ChEMBL |
| ZIMELDINE | CHEMBL37744 | Serotonin (5-HT) receptor antagonist | ANTAGONIST | ChEMBL |
1 to 10 of 11
See all 11 drugsTrials72
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07152184 | AMISULPRIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07103694 | LASMIDITAN | ClinicalTrials.gov | ||
| NCT06887621 | AMISULPRIDE | PHASE2 | ClinicalTrials.gov | |
| NCT06677229 | ELETRIPTAN HYDROBROMIDE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06585540 | AMISULPRIDE | PHASE3 | ClinicalTrials.gov | |
| NCT06581302 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT06267664 | LASMIDITAN | ClinicalTrials.gov | ||
| NCT06040944 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT05956600 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT05903040 | LASMIDITAN | ClinicalTrials.gov |
1 to 10 of 72
See all 72 trialsNIH grants290
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | HTR1F papers | Newest fiscal year |
|---|---|---|---|
| I01BX000851 | 5-HT Stimulation of Mitochondrial Biogenesis and Acute Kidney Injury | 2 | 2025 |
| P30AG066509 | University of Washington Alzheimer's Disease Research Center | 2 | 2025 |
| P30CA014089 | University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG) | 2 | 2025 |
| P30CA118100 | University of New Mexico Cancer Center Support Grant | 2 | 2025 |
| DP1DA054343 | Epigenomic labeling of cells that drive drug abuse behavior | 1 | 2025 |
| F30AG082394 | Boosting protein synthesis using antisense oligonucleotides to treat neurodegeneration | 1 | 2025 |
| F30MH136688 | Antisense oligonucleotide-based upregulation of neurodevelopmental disorder gene MYT1L | 1 | 2025 |
| K01EB032898 | Microstructure and connectivity modeling from the cortex to the spinal cord in Multiple Sclerosis | 1 | 2025 |
| P20GM103430 | Rhode Island IDeA Network of Biomedical Research Excellence | 1 | 2025 |
| P20GM103436 | IDeA Networks of Biomedical Research Excellence in Kentucky | 1 | 2025 |
1 to 10 of 290Source NIH's project files
See all 290 nih grantsPapers407
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Emerging pharmacological targets in migraine therapy: CGRP and beyond. | Front Pharmacol | 2026 | 42781272 | PubTator, text mining | PubMed |
| Mitochondria in Renal Ischemia-Reperfusion Injury: From Mechanisms to Therapeutics. | Biomedicines | 2026 | 41751208 | PubTator, text mining | PubMed |
| Monoaminergic Networks of Cognitive and Behavioral Symptoms in Early Parkinson's Disease. | Mov Disord | 2026 | 41618568 | PubTator, text mining | PubMed |
| Immune dysfunction contributes to comorbid depression in patients with multiple sclerosis. | J Affect Disord | 2026 | 41605342 | PubTator, text mining | PubMed |
| Antecedent enhancer activity predicts future susceptibility to seizures in mice. | Nat Commun | 2026 | 41507153 | PubTator, text mining | PubMed |
| RNA-Seq reveals flight-induced changes in cerebellar transcriptomic profiles of racing pigeons. | Genomics | 2026 | 41475467 | PubTator, text mining | PubMed |
| Structure-guided rational design of dual-target CGRP antagonist/5HT1F agonist therapeutics for migraine. | Eur J Med Chem | 2026 | 41270648 | PubTator, text mining | PubMed |
| Association of HTR1F with Prognosis, Tumor Immune Microenvironment, and Drug Sensitivity in Cancer: A Multi-Omics Perspective. | Biomedicines | 2025 | 41007799 | PubTator, text mining | PubMed |
| Exploring the epigenetic modifications of the RONS-TRPA1-CGRP axis in migraine pathophysiology. | J Headache Pain | 2025 | 40890590 | PubTator, text mining | PubMed |
| Comparison of the effectiveness of first-line preventive treatment of migraine in primary care: study protocol for a pragmatic clinical trial (PREMI study). | Trials | 2025 | 40859286 | PubTator, text mining | PubMed |
1 to 10 of 407
See all 407 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3355
GET https://conductscience.org/api/genes/v1/3355/patents?page=2